Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 25, 2008

View Archived Issues

Antinociceptive effects seen with TQ-1019 in models of painful HIV neuropathy

CG-100649 preclinical profile and phase I data described

Everolimus improves progression-free survival in metastatic renal cell carcinoma patients

New agents for cardiovascular disorders described in recent BioMarin and Suntory patents

Novel treatment option for HBV infection disclosed in recent patent

Remoxy oxycodone formulation effective in treating osteoarthritis pain

Delcath expands phase III percutaneous hepatic perfusion trial in melanoma

New glucocorticoid receptor modulator identified at GSK

ARYx announces successful results of chronic constipation trial with ATI-7505

Chemokine receives Hong Kong approval to initiate phase II CTCE-9908 trial

FDA grants fast track designation for OncoGenex's anticancer agent OGX-011

Human Genome Sciences initiates dosing in phase II HGS-ETR1 trial in NSCLC

Data on development of EHT-0202 for Alzheimer's disease presented

FDA approves Aloxi capsules for prevention of chemotherapy-induced nausea

FDA approves Nplate for adult chronic immune thrombocytopenic purpura

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...